Alternative health plan designs are moving from niche to mainstream. For decades, employers managed healthcare costs with the same tools: higher deductibles, narrower networks, and increased cost sharing. A more meaningful shift is now gaining momentum. According to...

Commercial healthcare costs are on track to rise 9% in 2027, according to a new analysis from PwC. That would be the highest medical cost trend in nearly two decades. The individual market is projected to increase 8.5%. PwC also revised its 2026 estimates upward,...

Novo Nordisk launched an oral version of its weight loss drug Wegovy on January 5, 2026, and the numbers since then have been hard to ignore. In roughly five months, the pill crossed 3 million prescriptions in the U.S., a pace the company describes as one of the...

Karleigh McClain did everything she thought she was supposed to do. She researched her options, signed up with a reputable-seeming telehealth company, met virtually with a provider, and started a weight loss medication that had helped her lose 50 pounds just a few...

For the first time in its history, Medicare is preparing to cover weight loss drugs at scale. Beginning July 1, 2026, the new Medicare GLP-1 Bridge will give eligible Part D beneficiaries access to medications like Wegovy, Zepbound, and the newly approved Foundayo for...

The Centers for Medicare and Medicaid Services refreshed its Overall Hospital Quality Star Rating this week, and the new numbers tell a familiar story. Most American hospitals are clustered in the middle of the distribution, with a small group of standouts at the top,...

https://www.youtube.com/watch?v=WQDsMje-WPE Medicare is about to do something it has never done before: cover prescription weight loss drugs. Starting July 1, 2026, eligible Medicare beneficiaries can get Wegovy, Zepbound, or Foundayo for just $50 a month through a...

Most people already know health care is expensive, but the numbers tell a stark story. About 6 in 10 adults say they are very or somewhat worried about affording health care for themselves and their families, making it the top financial concern, ahead of food and...

For years, the promise of GLP-1 weight loss treatment came with a catch: a weekly injection. Now, for the millions of Americans who would rather skip the needle entirely, two oral alternatives are on the market, and doctors say demand is real. Novo Nordisk's oral...

When Medicare Advantage insurers began sounding alarms about payment system changes last year, few could have predicted the scope of what followed. As 2025 drew to a close, more than 2.6 million Americans found out that the Medicare Advantage plan they'd chosen and...